News•Mar 16, 2026
The Peptide Boom Is Getting Out of Hand
The Atlantic outlines a surge in off‑label and experimental peptide use, noting that Vyleesi—approved for women’s hypoactive sexual desire disorder—is being bought by men through “research use only” listings and online pharmacies. Compounding pharmacies and telehealth firms now market customized peptide blends for weight loss, sexual performance, and recovery, exploiting regulatory gray zones. The FDA’s limited enforcement allows a sprawling underground market, while HHS Secretary Robert F. Kennedy Jr. hints at loosening peptide restrictions. Together, these dynamics create a fast‑growing, largely unregulated bio‑hacking industry.
